Almirall SA (STU:E2Z) reports robust sales growth and improved financial metrics, despite challenges in the U.S. and Germany.

Evotec SE (NASDAQ:EVO) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 4, 2026, Evotec SE (NASDAQ:EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance with Almirall focused on medical dermatology. The program is aimed at developing new therapies for immune-mediated […]

Why Almirall (BME:ALM) is Back on Watchlists Almirall (BME:ALM) has drawn fresh attention after recent share price moves, with the stock showing a mix of gains over the past month and weaker performance over the past three months. See our latest analysis for Almirall. Recent trading has been mixed, with a 0.79% 1 day share price return and an 11.71% 30 day share price return set against a small year to date share price decline and a 38.46% 1 year total shareholder return. This suggests that...

Almirall’s latest earnings and guidance snapshot Almirall (BME:ALM) has drawn fresh attention after releasing full year 2025 results alongside new 2026 guidance, combining updated profit figures with a projected 9% to 12% net sales increase for the year ahead. See our latest analysis for Almirall. Despite the fresh 2025 results and 2026 net sales guidance, Almirall’s recent short term share price return has been weak, with a 1 day move of 3.06% lower and a 7 day decline of 6.39%. That...

Almirall SA (LBTSF) reports a robust 12.4% increase in net sales and strategic advancements despite market challenges.

Investing.com -- Almirall SA’s eczema biologic Ebglyss tripled sales in its second year on the European market and edged past analyst forecasts, the Barcelona-based dermatology specialist said on Monday, as the company’s 2026 profit guidance signalled the first signs of meaningful margin expansion from the drug’s growing contribution.

Almirall overview and recent share performance Almirall (BME:ALM) has drawn investor attention after recent trading, with the share price at €12.62 and mixed returns, including a 3% gain over the past 3 months but a 2% decline year to date. See our latest analysis for Almirall. Recent trading has been choppy, with a 1-day share price return of 2.77% contrasting with softer short term moves. Meanwhile, a 1-year total shareholder return of 34.71% points to stronger momentum over a longer...

Almirall (BME:ALM) shares edged higher today, gaining just under 2%. This move has caught the attention of investors, who are keen to understand what might be driving sentiment for the Spanish pharmaceutical company. See our latest analysis for Almirall. Today’s small jump adds to Almirall’s solid year-to-date momentum, with a 40.9% share price return since January and a robust 42.6% total shareholder return over the past 12 months. Recent price action has been encouraging, building on the...

Almirall SA (FRA:E2Z) reports a robust 13% increase in net sales, driven by European dermatology, while navigating challenges in gross margin and SG&A expenses.